본문 바로가기
KERD
논문KCI 등재

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study

Yang Li|Wen-Hui Chen|Xiang Guo|Chong Zhao|Lin-Quan Tang|Ling Guo|Dong-Hua Luo|Hao-Yuan Mo|Mu-Sheng Zeng|Li-Ting Liu|Shan-Shan Guo|Qing-Nan Tang|Hai-Qiang Mai|Qiu-Yan Chen|Shao-Yan Guo|Tong-Yu Lu|Bo-Lin Chen|Qi-Yu Zhong|Meng-Sha Zou|Rui Sun|Ka-Jia Cao|Chao-Nan Qian
대한암학회 (Korean Cancer Association)|2018.07|Cancer Research and Treatment|제50권 제3호|pp. 861-871

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

PrognosisEpstein-Barr virusNasopharyngeal carcinomaTumor burdenIntensity modulated radiotherapy
주제분류의학일반

초록

Purpose Little is known about combination of the circulating Epstein-Barr viral (EBV) DNA and tumor volume in prognosis of stage II nasopharyngeal carcinoma (NPC) patients in the intensity modulated radiotherapy (IMRT) era. We conducted this cohort study to evaluate the prognostic values of combining these two factors. Materials and Methods By Kaplan-Meier, we compare the differences of survival curves between 385 patients with different EBV DNA or tumor volume levels, or with the combination of two biomarkers mentioned above. Results Gross tumor volume of cervical lymph nodes (GTVnd, p < 0.001) and total tumor volume (GTVtotal, p < 0.001) were both closely related to pretreatment EBV DNA, while gross tumor volume of nasopharynx (GTVnx, p=0.047) was weakly related to EBV DNA. EBV DNA was significantly correlated with progress-free survival (PFS, p=0.005), locoregional-free survival (LRFS, p=0.039), and distant metastasis-free survival (DMFS, p=0.017), while GTVtotal, regardless of GTVnx and GTVnd, had a significant correlation with PFS and LRFS. The p-values of GTVtotal for PFS and LRFS were 0.008 and 0.001, respectively. According to GTVtotal and pretreatment EBV DNA level, patients were divided into a low-risk group (EBV DNA 0 copy/mL, GTVtotal < 30 cm3; EBV DNA 0 copy/mL, GTVtotal  30 cm3; or EBV DNA > 0 copy/mL, GTVtotal < 30 cm3) and a high-risk group (EBV DNA > 0 copy/mL, GTVtotal  30 cm3). When patients in the low-risk group were compared with those in the high-risk group, 3-year PFS (p=0.003), LRFS (p=0.010), and DMFS (p=0.031) rates were statistically significant. Conclusion Pretreatment plasma EBV DNA and tumor volume were both closely correlated with prognosis of stage II NPC patients in the IMRT era. Combination of EBV DNA and tumor volume can refine prognosis and indicate for clinical therapy.

Abstract

Purpose Little is known about combination of the circulating Epstein-Barr viral (EBV) DNA and tumor volume in prognosis of stage II nasopharyngeal carcinoma (NPC) patients in the intensity modulated radiotherapy (IMRT) era. We conducted this cohort study to evaluate the prognostic values of combining these two factors. Materials and Methods By Kaplan-Meier, we compare the differences of survival curves between 385 patients with different EBV DNA or tumor volume levels, or with the combination of two biomarkers mentioned above. Results Gross tumor volume of cervical lymph nodes (GTVnd, p < 0.001) and total tumor volume (GTVtotal, p < 0.001) were both closely related to pretreatment EBV DNA, while gross tumor volume of nasopharynx (GTVnx, p=0.047) was weakly related to EBV DNA. EBV DNA was significantly correlated with progress-free survival (PFS, p=0.005), locoregional-free survival (LRFS, p=0.039), and distant metastasis-free survival (DMFS, p=0.017), while GTVtotal, regardless of GTVnx and GTVnd, had a significant correlation with PFS and LRFS. The p-values of GTVtotal for PFS and LRFS were 0.008 and 0.001, respectively. According to GTVtotal and pretreatment EBV DNA level, patients were divided into a low-risk group (EBV DNA 0 copy/mL, GTVtotal < 30 cm3; EBV DNA 0 copy/mL, GTVtotal  30 cm3; or EBV DNA > 0 copy/mL, GTVtotal < 30 cm3) and a high-risk group (EBV DNA > 0 copy/mL, GTVtotal  30 cm3). When patients in the low-risk group were compared with those in the high-risk group, 3-year PFS (p=0.003), LRFS (p=0.010), and DMFS (p=0.031) rates were statistically significant. Conclusion Pretreatment plasma EBV DNA and tumor volume were both closely correlated with prognosis of stage II NPC patients in the IMRT era. Combination of EBV DNA and tumor volume can refine prognosis and indicate for clinical therapy.

참고문헌 (29)

  1. Choa G, "Nasopharyngeal carcinoma. Some observations on the clinical features and technique of examination", Pac Med Surg, 75, pp.172~174 (1967)
  2. Cao SM, "The prevalence and prevention of nasopharyngeal carcinoma in China", Chin J Cancer, 30, pp.114~119 (2011)[DOI]
  3. Lee AW, "The battle against nasopharyngeal cancer", Radiother Oncol, 104, pp.272~278 (2012)[DOI]
  4. Wee JT, "Is nasopharyngeal cancer really a "Cantonese cancer"?", Chin J Cancer, 29, pp.517~526 (2010)[DOI]
  5. Chen QY, "Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial", J Natl Cancer Inst, 103, pp.1761~1770 (2011)[DOI]
  6. Lai SZ, "How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients", Int J Radiat Oncol Biol Phys, 80, pp.661~668 (2011)[DOI]
  7. Peng G, "A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma", Radiother Oncol, 104, pp.286~293 (2012)[DOI]
  8. Su Z, "Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study", Tumour Biol, 37, pp.4429~4438 (2016)[DOI]
  9. Zhang F, "Efficacy of concurrent chemotherapy for intermediate risk NPC in the intensity-modulated radiotherapy era: a propensity-matched analysis", Sci Rep, 5, pp.17378~ (2016)
  10. Ji MF, "Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China", Cancer, 120, pp.1353~1360 (2014)[DOI]
  11. Wei WI, "Nasopharyngeal carcinoma", Lancet, 365, pp.2041~2054 (2005)[DOI]
  12. Mutirangura A, "Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma", Clin Cancer Res, 4, pp.665~669 (1998)
  13. Chan AT, "Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma", J Natl Cancer Inst, 94, pp.1614~1619 (2002)[DOI]
  14. Lo YM, "Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma", Cancer Res, 59, pp.1188~1191 (1999)
  15. Lin JC, "Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma", N Engl J Med, 350, pp.2461~2470 (2004)[DOI]
  16. Chen MK, "Better prediction of prognosis for patients with nasopharyngeal carcinoma using primary tumor volume", Cancer, 100, pp.2160~2166 (2004)[DOI]
  17. Chua DT, "Volumetric analysis of tumor extent in nasopharyngeal carcinoma and correlation with treatment outcome", Int J Radiat Oncol Biol Phys, 39, pp.711~719 (1997)[DOI]
  18. Ma J, "Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories", Clin Cancer Res, 13, pp.1445~1452 (2007)[DOI]
  19. fluorodeoxyglucose positron emission tomography, "computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging", J Clin Oncol, 31, pp.2861~2869 (2013)[DOI]
  20. Zhao C, "Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma", Ai Zheng, 23(11 Suppl), pp.1532~1537 (2004)
  21. Chen WS, "Application of combined detection of EBV VCA-IgA and EA-IgA antibodies in the diagnosis of NPC", J Trop Med, 10, pp.434~436 (2010)
  22. Cho W, "Molecular biomarker discovery and progress in nasopharyngeal carcinoma", Cancer Res, 67(9 Suppl) (2007)
  23. Chen M, "Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma", Biomed Res Int, 2015, pp.617949~ (2015)
  24. Chen WH, "Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era", Medicine (Baltimore), 95, pp.e2642~ (2016)[DOI]
  25. Lo YM, "Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma", Cancer Res, 60, pp.2351~2355 (2000)
  26. Guo Q, "Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era", Jpn J Clin Oncol, 46, pp.241~247 (2016)[DOI]
  27. Ma BB, "Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma", Int J Radiat Oncol Biol Phys, 66, pp.714~720 (2006)[DOI]
  28. Hou X, "Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy", Clin Oncol (R Coll Radiol), 23, pp.128~133 (2011)[DOI]
  29. Ma BB, "The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma", Oral Oncol, 44, pp.1067~1072 (2008)[DOI]

이 간행물의 다른 논문 (39건)

Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer박종태, 김승일, 양반석, 이학우, 이승아, 안성귀, 정준, 이학민pp. 625-633Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy?윤성현, 오보영, 박윤아, 이우용, 허정욱, 전호경, 조용범, 김희철pp. 634-645Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma양승현, 김경진, 이은정, 전경희, 성진실, 차혜정, 이서진, 김지혜, 송준규pp. 646-657BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database김광수, 장지현, 정세희, 오소희, 최인실, 김영아, 이종윤, 황기태pp. 658-669Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type정선회, 이주연, 김일한, 허대석, 조윤숙, 김미소, 김범석, 김동완, 옥찬영, 김태민, 김현지, 이성희pp. 670-680
원문 보기